pharmaceutical investing Sorrento Therapeutics Subsidiary, Scilex, Receives US FDA Approval for Non-Opioid ZTlido
medical device investing Cambrex Expands Process Research and Development Capabilities Across North America
IntelGenx Strengthens Partnership with Chemo Group by Signing a Co-Development Term Sheet for an Additional Product
Lahontan Announces 22% Increase in Mineral Resources at Santa Fe: 1,195,000 Au Eq oz Indicated, and 1,190,000 Au Eq oz Inferred
Premier American Uranium Identifies Multiple Mineralized Uranium Trends in Ongoing Drilling at Kaycee, Wyoming
